Scientific Opinion on the substantiation of health claims related to conjugated linoleic acid (CLA) isomers and contribution to the maintenance or achievement of a normal body weight (ID 686, 726, 1516, 1518, 2892, 3165), increase in lean body mass (ID 498, 731), increase in insulin sensitivity (ID 1517), protection of DNA, proteins and lipids from oxidative damage (ID 564, 1937), and contribution to immune defences by stimulation of production of protective antibodies in response to vaccination (ID 687, 1519) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to conjugated linoleic acid (CLA) isomers and contribution to the maintenance or achievement of a normal body weight, increase in lean body mass, increase in insulin sensitivity, protection of DNA, proteins and lipids from oxidative damage, and contribution to immune defences by stimulation of production of protective antibodies in response to vaccination. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claims is an equimolar mixture of the conjugated linoleic acid (CLA) isomers c9, t11 and t10, c12. The Panel considers that an equimolar mixture of the conjugated linoleic acid (CLA) isomers c9, t11 and t10, c12, is sufficiently characterised.